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Summary. Cardiovascular disease (CVD) remains the major cause of 
death and there is the need to a better stratification of CVD patients. By 
an unbiased statistical approach we sought to identify clusters of patients 
to better stratify their risk. 202 patients with chest pain (63% males, age 
62±12 yr) undergone to CT coronary angiography (CCTA) were 
prospectively included and classified using K-means cluster analysis of 
clinical, imaging and bio-humoral data. The most relevant classification 
resulted in three phenotypes distinguished according to Framingham 
score and HMW adiponectin plasma levels. Presence and severity of 
disease as assessed by CCTA were verified trough these phenotypes. By 
K-means cluster analysis, we identified CVD phenotypes allowing to 
stratify patients requiring different diagnostic and therapeutic approach. 
 
Introduction. Despite effective prevention strategies, cardiovascular 
disease (CVD) is the leading cause of death worldwide (1) and its 
prevention represents an urgent need of Health Systems in order to invert 
the trends of the estimated sanitary costs (2). Since CVD risk is 
heterogeneous within CVD patients due to the multi-factorial etiology of 
disease, and despite the value of traditional risk factors, approximately 
half of patients had only one or none of these risk factors and, conversely, 
individuals with few clinical risk experience the largest number of 
cardiovascular events (3). Accordingly, early detection of CAD in 
apparently healthy persons may be an important issue for supplement to 
the risk assessment based on the traditional risk factors. Thus, updated 
and improved strategies for the primary prevention of CAD are needed, 
especially in patients with new onset of chest pain. Recently, interest has 
emerged for the identification of clinical CVD phenotypes , as defined by 
‘‘a single or combination of disease attributes that describe difference 
between individuals with CVD as they relate to clinically diagnoses’’ (3). 
In the present study, we performed a cluster analysis using multiple 
variables (including clinical evaluation, biohumoral profile, and imaging) 
obtained in a cohort of subjects with suspected coronary artery disease 
(CAD). The clinical relevance of these clusters of subjects was validated 
using data regarding presence and severity of CAD obtained during CT 
coronary angiography (CCTA) evaluation. The aim of this study was to 
examine whether clusters of patients identified with an unsupervised 
approach differed in CAD. 
 
Material and Methods. We prospectively included 202 consecutive 
patients with suspected CAD (63% males, age 62±12 yr). Demographic 
and clinical characteristic were obtained at the time of inclusion in the 
study. Bio-humoral analysis included molecules associated to the 
atherosclerosis and involved in metabolism, inflammation, vascular 
remodeling and endothelial function. Cardiovascular risk estimation was 
assessed by Framingham Risk Score (FRS) for low risk populations. 
Presence of atherosclerosis (stenosis >30%) and of significant stenosis 
(stenosis >50%) were evaluated by an interactive application on 
multiplanar reformatting CCTA reconstruction. Patients were classified 
using K-means cluster analysis of clinical, bio-humoral and imaging data. 
Our strategy was to combine continuous data in a single cluster analysis 
aimed at the identification of CVD phenotypes. The relevance of this 
classification was validated using presence and extent of atherosclerosis 
as assessed by CCTA. A p=0.05 was considered statistically significant. 
Analyses were performed using the SAS 9.2 statistical software (Cary, 
North Carolina, USA). 
 
Results. The most relevant patient classification resulted in three 
phenotypes distinguished according to FRS score and high molecular 
weight (HMW) adiponectin plasma levels (Figure 1). Phenotype 1 (n=39) 
included subjects at very high CVD risk (FRS 34.6±9.7%), who had very 
low levels of HMW adiponectin (1.6±1.3 g/mL). Phenotype 2 (n=124) 
included subjects with low FRS (11.8±5.4%) and low HMW adiponectin 
(1.9±1.1 g/mL). Phenotype 3 (n=16) included the less severe patients 
with FRS 8.1±4.5% and high levels of HMW adiponectin (7.8±2.8 
g/mL). As assessed by CCTA analysis, atherosclerosis and CAD were 
present in 67% and 40% of patients, respectively. 40%, 26% and 34% of 
CAD patients showed a 1-, 2-, 3-vessels disease, respectively. Presence 
and severity of both atherosclerosis and CAD were significantly identified 
trough these phenotypes (Figure2). 
 Conclusions. In this population of subjects with suspected CAD, we 
identified three phenotypes, including one phenotype (Phenotype 1) at 
high risk of CVD and very low levels of HMW adiponectin plasma levels, 
and two distinct phenotypes (Phenotype 2 and 3) at low-intermediate risk 
of CVD, further distinguished by low and high HMW adiponectin plasma 
levels, respectively. Moreover, these phenotypes were able to stratify 
patients in different pathological conditions, such as presence and severity 
of both atherosclerosis and CAD. These findings suggest that different 
strategies for improving diagnosis and prognosis should be proposed to 
these groups of patients. Plasma levels of HWM adiponectin could be 
integrated in these new strategies in order to increase their performance. 
Adiponectin, a major adipocyte-secreted protein, exerts antidiabetic, anti-
atherogenic and anti-inflammatory activities (4). These data confirmed 
the diagnostic/prognostic value of adiponectin in CVD, as recently 
suggested, and indicate HMW adiponectin (5) as a relevant biomarker for 
patients at increased cardiometabolic risk.  
In conclusion, with an unbiased statistical approach we sought to identify 
clusters of patients with chest pain and to better stratify their CVD risk. 
HMW adiponectin appears to have a specific role in a future integrated 
system of coronary risk stratification. 
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 Captions 
Figure 1: Biplot simultaneously providing information on both the 
samples and the variables of the data matrix in a two-dimensional 
representation. The samples are represented as points, while the variables 
are represented as calibrated axes. Phenotypes are distinguished by 
different colors. Additional descriptors as circles represent the 
classification regions. 
Figure 2: Mosaic plot illustrating the results of the cluster analysis. 
Pathological conditions (presence of aterosclerosis, severity of disease 
and number of diseased vessels) are reported on vertical lines and are 
distinguished by different colors. Phenotypes are reported on orixontal 
lines. In each pathological conditions, cluster analysis significantly 
stratified patients allowing their distribution in three groups: phenotyphe 
3 group contained pathological subjects, while phenotyphe 1 group  
contained healthy subjects. 
 
